HER2+ Gastric Cancer Market to Observe Impressive Growth by 2030, Evaluates DelveInsight | Key Companies – Roche, AstraZeneca, Astellas Pharma, RemeGen, and Others
The HER2+ Gastric Cancer market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2017 to 2030. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
HER2+ Gastric Cancer: An Overview
The stomach is the most commonly involved site (60%-75%) in the gastrointestinal tract followed by the small bowel, ileocecal region, and rectum. Several different types of cancer can occur in the stomach. The most common type is called adenocarcinoma. Approximately 90% of gastric cancers are adenocarcinoma, although it is uncommon in the United States. It occurs most often in men over age 40.
HER2+ Gastric Cancer Market Key Facts
-
There is a higher incidence of gastric cancer in non-Caucasian populations. In the United States, the highest incidence is found in the Native American (21.6/100,000) and Asian (20/100,000) populations. Both race and sex affect the risk of disease development and subsequent mortality rate. The highest mortality rate based upon ethnic/sex combination is African-American males (12.4/100 000). However, there are similar overall 5-year survival rates among the different races.
-
Gastric carcinoma (GC) is the fourth most common malignancy worldwide (989,600 new cases per year in 2008) and remains the second cause of death (738,000 deaths annually) of all malignancies worldwide. The disease becomes symptomatic in an advanced stage. The five-year survival rate is relatively good only in Japan, where it reaches 90%. In European countries, survival rates vary from 10% to 30% High survival rate in Japan is probably achieved by early diagnosis by endoscopic examinations and consecutive early tumor resection.
-
Males have a higher prevalence of HER2+ Gastric Cancer as compared to females.
-
HER2-overexpression in gastric cancer is dependent on the location of the primary tumor and ranges between 6–30%. The reported rates of HER2-positivity are highest in the gastro-esophageal junction (GEJ) or stomach cardiac tumors compared to tumors arising more distally in the stomach.
The market size of HER2+ Gastric Cancer market size is anticipated to increase during the study period owing to the increasing Incidence population of patients and the launch of emerging therapies.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted HER2+ Gastric Cancer market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the HER2+ Gastric Cancer market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Get the PDF Sample of the Report:- HER2+ Gastric Cancer Therapeutics Market
HER2+ Gastric Cancer Epidemiology
The epidemiology section covers insights about the historical and current HER2+ Gastric Cancer patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
HER2+ Gastric Cancer Epidemiology Segmentation
-
Total Treatable Pool of HER2+ Gastric Cancer
-
Diagnosed Incidence Pool of HER2 positive Gastric Cancer
-
Stage-specific Pool of HER2+ Gastric Cancer
-
Gender-specific Pool of HER2+ Gastric Cancer
HER2+ Gastric Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the HER2+ Gastric Cancer market or expected to get launched in the market during the study period. The analysis covers HER2+ Gastric Cancer market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the HER2+ Gastric Cancer Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
HER2+ Gastric Cancer Therapeutics Analysis
The dynamics of the HER2+ Gastric Cancer market are anticipated to grow due to the improvement in healthcare spending across the world and the launch of emerging therapies.
Owing to the extensive research and development activities of pharmaceutical companies, along with the expected launch of approved therapies, the HER2+ Gastric Cancer therapeutics segment is expected to transform immensely in the coming years.
Key companies in the HER2+ Gastric Cancer Market include:
-
Roche
-
AstraZeneca
-
Astellas Pharma
-
RemeGen
And many others.
HER2+ Gastric Cancer Therapies covered in the report includes:
-
RC48
-
Enhertu
-
Zolbetuximab
-
Herceptin
And many more.
Get More Detailed Insights into the Emerging Therapies & Key Companies:- https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-market
Table of Content
1. Key Insights
2. Executive Summary
3. HER2+ Gastric Cancer Competitive Intelligence Analysis
4. HER2+ Gastric Cancer Market Overview at a Glance
5. HER2+ Gastric Cancer Disease Background and Overview
6. HER2+ Gastric Cancer Patient Journey
7. HER2+ Gastric Cancer Epidemiology and Patient Population
8. HER2+ Gastric Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. HER2+ Gastric Cancer Unmet Needs
10. Key Endpoints of HER2+ Gastric Cancer Treatment
11. HER2+ Gastric Cancer Marketed Products
12. HER2+ Gastric Cancer Emerging Therapies
13. HER2+ Gastric Cancer Seven Major Market Analysis
14. Attribute Analysis
15. HER2+ Gastric Cancer Market Outlook (7 major markets)
16. HER2+ Gastric Cancer Access and Reimbursement Overview
17. KOL Views on the HER2+ Gastric Cancer Market.
18. HER2+ Gastric Cancer Market Drivers
19. HER2+ Gastric Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Request Sample Report here:- https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
